Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Bithionol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.74 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.74 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.74 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.74 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.74 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.34 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.34 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.78 |
| ▸ | HPGD | P15428 | 5/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.78 |
| ▸ | MEN1 | O00255 | 4/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.78 |
| ▸ | RECQL | P46063 | 3/20 | 0.78 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bithionol SCHEMBL636173 | 0.88 | HPGD (1.00) | HSD17B10HPGDCYP3A4MEN1KMT2A | |
| Bithionol SCHEMBL31349894 | 0.88 | HPGD (1.00) | HSD17B10HPGDCYP3A4MEN1KMT2A | |
| Bithionol SCHEMBL64385 | 0.86 | HSD17B10 (1.00) | HSD17B10HPGDCYP3A4MEN1KMT2A | |
| Bithionol SCHEMBL29352300 | 0.86 | HSD17B10 (1.00) | HSD17B10HPGDCYP3A4MEN1KMT2A | |
| Bithionol SCHEMBL23926397 | 0.84 | HSD17B10 (0.95) | HSD17B10HPGDCYP3A4MEN1KMT2A | |
| Bithionol SCHEMBL29988662 | 0.84 | HSD17B10 (0.95) | HSD17B10HPGDCYP3A4MEN1KMT2A | |
| Bithionol SCHEMBL1158099 | 0.84 | HSD17B10 (0.95) | HSD17B10HPGDCYP3A4MEN1KMT2A | |
| Bithionol SCHEMBL10392807 | 0.84 | HSD17B10 (0.95) | HSD17B10HPGDCYP3A4MEN1KMT2A | |
| SCHEMBL12655293 | 0.79 | HSD17B10 (0.83) | HSD17B10HPGDCYP3A4MEN1KMT2A | |
| SCHEMBL14644985 | 0.76 | HSD17B10 (0.77) | HSD17B10HPGDCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-12637715-B2 | Biomarkers and uses therefor | GenoDx Pty Ltd (AU) | 2026-05-26 | — | — | US | disclosed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12514818-B2 | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | TRIS PHARMA, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1054998-A1 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000040604-A2 | METHODS AND COMPOSITIONS FOR MODULATING CYTOKINE RELEASE BY αEβ7-EXPRESSING CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-1999036570-A2 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE INC (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | SI, FABP2, FABP6 | ADORA3 1127/4885THRB 195/4885ADORA2A 1485/4885 |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | ADORA3 2019/4885THRB 24/4885ADORA2A 2147/4885 |
| US-12637715-B2 | Biomarkers and uses therefor | POLR2B, POLB, POLG | ADORA3 3704/4885THRB 1897/4885ADORA2A 3081/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | ADORA3 4503/4885THRB 2424/4885ADORA2A 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.